A Selective JAK inhibitor Shows Promise for Crohn Disease

A phase II trial demonstrates efficacy compared with placebo.

Source link

Related posts

Model May Predict Barrett Esophagus Diagnosis in GERD Patients


InSphero launches NAFLD, NASH cellular drug development platform


Potentially FDA-approved medications face significant scrutiny on their printed materials


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World

WeCreativez WhatsApp Support
Our customer support team is here to answer your questions. Ask us anything!
👋 Hi, how can I help?